These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 24215141)

  • 1. Microparticles of rifampicin: comparison of pulmonary route with oral route for drug uptake by alveolar macrophages, phagocytosis activity and toxicity study in albino rats.
    Parikh R; Patel L; Dalwadi S
    Drug Deliv; 2014 Sep; 21(6):406-11. PubMed ID: 24215141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhaled microparticles of antitubercular antibiotic for in vitro and in vivo alveolar macrophage targeting and activation of phagocytosis.
    Parikh R; Dalwadi S; Aboti P; Patel L
    J Antibiot (Tokyo); 2014 May; 67(5):387-94. PubMed ID: 24569669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of Inhaled Rifampicin Porous Particles for Tuberculosis Treatment: Insight into Rifampicin Absorption from the Lungs of Guinea Pigs.
    Garcia Contreras L; Sung J; Ibrahim M; Elbert K; Edwards D; Hickey A
    Mol Pharm; 2015 Aug; 12(8):2642-50. PubMed ID: 25942002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis.
    Sharma R; Saxena D; Dwivedi AK; Misra A
    Pharm Res; 2001 Oct; 18(10):1405-10. PubMed ID: 11697465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spray-dried particles as pulmonary delivery system of anti-tubercular drugs: design, optimization, in vitro and in vivo evaluation.
    Garg T; Goyal AK; Rath G; Murthy RS
    Pharm Dev Technol; 2016 Dec; 21(8):951-960. PubMed ID: 26334961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dry-Powder Inhaler Formulation of Rifampicin: An Improved Targeted Delivery System for Alveolar Tuberculosis.
    Rawal T; Kremer L; Halloum I; Butani S
    J Aerosol Med Pulm Drug Deliv; 2017 Dec; 30(6):388-398. PubMed ID: 28510480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delivery of ofloxacin to the lung and alveolar macrophages via hyaluronan microspheres for the treatment of tuberculosis.
    Hwang SM; Kim DD; Chung SJ; Shim CK
    J Control Release; 2008 Jul; 129(2):100-6. PubMed ID: 18538437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhaled Solid Lipid Microparticles to target alveolar macrophages for tuberculosis.
    Maretti E; Rossi T; Bondi M; Croce MA; Hanuskova M; Leo E; Sacchetti F; Iannuccelli V
    Int J Pharm; 2014 Feb; 462(1-2):74-82. PubMed ID: 24374224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rifampicin loaded chitosan nanoparticle dry powder presents an improved therapeutic approach for alveolar tuberculosis.
    Rawal T; Parmar R; Tyagi RK; Butani S
    Colloids Surf B Biointerfaces; 2017 Jun; 154():321-330. PubMed ID: 28363192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uptake of inhalable microparticles affects defence responses of macrophages infected with Mycobacterium tuberculosis H37Ra.
    Sharma R; Muttil P; Yadav AB; Rath SK; Bajpai VK; Mani U; Misra A
    J Antimicrob Chemother; 2007 Mar; 59(3):499-506. PubMed ID: 17242031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK; Kim JH; Kang H; Cho JS; Smego RA
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
    Kang WL; Xie YG; Tan WG; Chu NH; Li L; You YH; Yang YZ; Wang XM; Yan XL; Miao ZP; Duanmu HJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres in the treatment of tuberculosis in the guinea pig.
    Garcia-Contreras L; Sethuraman V; Kazantseva M; Godfrey V; Hickey AJ
    J Antimicrob Chemother; 2006 Nov; 58(5):980-6. PubMed ID: 16971416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delivery of rifampicin-PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis.
    Hirota K; Hasegawa T; Nakajima T; Inagawa H; Kohchi C; Soma G; Makino K; Terada H
    J Control Release; 2010 Mar; 142(3):339-46. PubMed ID: 19951729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Characterization of Nanoembedded Microparticles for Pulmonary Delivery of Antitubercular Drugs against Experimental Tuberculosis.
    Goyal AK; Garg T; Rath G; Gupta UD; Gupta P
    Mol Pharm; 2015 Nov; 12(11):3839-50. PubMed ID: 26436948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis.
    Ohashi K; Kabasawa T; Ozeki T; Okada H
    J Control Release; 2009 Apr; 135(1):19-24. PubMed ID: 19121349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid microsphere formulation containing rifampicin targets alveolar macrophages.
    Takenaga M; Ohta Y; Tokura Y; Hamaguchi A; Igarashi R; Disratthakit A; Doi N
    Drug Deliv; 2008; 15(3):169-75. PubMed ID: 18379929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis.
    Becerra MC; Freeman J; Bayona J; Shin SS; Kim JY; Furin JJ; Werner B; Sloutsky A; Timperi R; Wilson ME; Pagano M; Farmer PE
    Int J Tuberc Lung Dis; 2000 Feb; 4(2):108-14. PubMed ID: 10694087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.